Vericel (VCEL)
(Delayed Data from NSDQ)
$54.00 USD
+3.97 (7.94%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $54.06 +0.06 (0.11%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.00 USD
+3.97 (7.94%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $54.06 +0.06 (0.11%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Zacks News
Vericel Corporation (VCEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VCEL) Outperforming Other Medical Stocks This Year?
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y
by Zacks Equity Research
CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.
Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug
by Zacks Equity Research
The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.
Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?
by Zacks Equity Research
Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).
Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings
by Zacks Equity Research
LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.
Vericel Corporation (VCEL) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Vericel, Intuit, Mosaic, Ally Financial and D.R. Horton highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vericel, Intuit, Mosaic, Ally Financial and D.R. Horton highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
Zacks Market Edge Highlights: Vericel, Tesla, Chewy, Alibaba and Facebook
by Zacks Equity Research
Zacks Market Edge Highlights: Vericel, Tesla, Chewy, Alibaba and Facebook
Should You Sell Your Big Winner Stocks?
by Tracey Ryniec
One of the most difficult parts of investing is knowing when to sell your stocks. After a red hot 2020, what should you do?
Stock Investors: What's the Next Hot Industry?
by Tracey Ryniec
Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.
Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gives this small-cap big upside
Vericel Corp (VCEL) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.
Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.
Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.
Do Options Traders Know Something About Vericel (VCEL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
Dump These 4 Toxic Stocks or Sell Short for Timely Profits
by Zacks Equity Research
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems
by Zacks Equity Research
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems
Dump These 5 Toxic Stocks Right Away
by Zacks Equity Research
Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.